Search Results 71-80 of 21206 for Inhibition

  1. Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults - Mayo Clinic

    About this study. This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same ...

  2. Andrea E. Wahner Hendrickson, M.D. - Mayo Clinic Faculty Profiles

    MTH1 inhibition for ovarian cancer. In collaboration with Oxcia AB, Dr. Wahner Hendrickson is investigating a first-in-human MTH1 inhibitor and its impact on ...

  3. Frontotemporal dementia - Symptoms and causes - Mayo Clinic

    Loss of inhibition. Lack of interest, also known as apathy. Apathy can be mistaken for depression. Compulsive behaviors such as tapping, clapping, or ...

  4. GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC - Mayo Clinic

    The purpose of this study is to evaluate whether CAN-2409 + prodrug added to standard of care immune checkpoint inhibitor (ICI) therapy will be safe and improve ...

  5. Clinical trials - Mayo Clinic Research

    ... inhibitor in cancer called MTI-301 (also known as SSI-4). We have developed a novel small molecule inhibitor blocking the activity of an enzyme, stearoyl ...

  6. Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas - Mayo Clinic

    The purpose of this study is to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336, a selective enzyme blocker, ...

  7. Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment - Mayo Clinic

    RATIONALE: Testosterone may help relieve moderate or severe arthralgia associated with the use of aromatase inhibitors, such as anastrozole or letrozole.

  8. Clinicopathological and Molecular Characteristics Associated With Acquired Resistance to Kinase Inhibitors in Thyroid Cancer - Mayo Clinic

    Clinicopathological and Molecular Characteristics Associated With Acquired Resistance to Kinase Inhibitors in Thyroid Cancer · More about research at Mayo Clinic.

  9. Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors - Mayo Clinic

    The purpose of this study is to determine the extent to which PARP inhibitor (PARPi) treatment reduces systemic levels of mesenchymal stem cell (MSC)-derived ...

  10. Dual BET And CBP/p300 Inhibitor In Patients With Targeted Advanced Solid Tumors And Hematological Malignancies - Mayo Clinic

    About this study. A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and ...